JP Patent

JP7825636B2 — （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態

Assigned to Pierre Fabre Medicament SA · Expires 2026-03-06 · 0y expired

What this patent protects

Patent listed against mirdametinib.

Drugs covered by this patent

Patent Metadata

Patent number
JP7825636B2
Jurisdiction
JP
Classification
—
Expires
2026-03-06
Drug substance claim
No
Drug product claim
No
Assignee
Pierre Fabre Medicament SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.